Completed PHASE1 INTERVENTIONAL 8-arm NCT02156388

Safety and Pharmacokinetic(PK) Study of GW003 to Metastatic Tumors

A Single-center, Uncontrolled, Open, Phase 1 Study of Recombinant(Expressed by Pichia Pastoris) Human Serum Albumin/Human Granulocyte-Colony Stimulating Factor(I)Fusion Protein For Injection(GW003)to Metastatic Tumors

Sponsor: Jiangsu T-Mab Biopharma Co.,Ltd

Conditions Chemotherapy-induced Neutropenia Metastatic Tumors

Interventions GW003

Updated 5 times since 2017 Last updated: Feb 22, 2016 Started: Aug 31, 2013 Primary completion: Feb 28, 2015 Completion: Dec 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Chemotherapy-induced Neutropenia and Metastatic Tumors and is currently completed. Jiangsu T-Mab Biopharma Co.,Ltd leads this study, which shows 5 recorded versions since 2013 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Aug 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jiangsu T-Mab Biopharma Co.,Ltd

Data source: Jiangsu T-Mab Biopharma Co.,Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tianjin, China